Conference Coverage

Depression, Cognitive Impairment Often Complicate Multiple Sclerosis


 

EXPERT ANALYSIS FROM THE ANNUAL CONGRESS OF THE EUROPEAN COLLEGE OF NEUROPSYCHO-PHARMACOLOGY

Dr. John DeLuca

While disease-modifying therapies appear to have little impact on cognitive deficits, a modified approach to learning can make a substantial difference, said Dr. DeLuca, who is also professor of physical medicine and rehabilitation at New Jersey Medical School, Newark. Helpful measures include having patients "slow things down" when attempting to learn something, and asking questions to make sure they understand something correctly. MS patients also find that self-testing on new information helps strengthen their encoding. These patients "learn by slowing down and going over material again and again and testing themselves, which has a huge effect," he said in an interview. "It sounds simplistic, but this is the primary intervention."

Dr. Feinstein said that he has received honoraria and grant support from Teva, Merck-Serono, and Bayer. Dr. DeLuca said that he has been a consultant to and received grant support from Biogen and Memen Pharmaceuticlas.

Pages

Recommended Reading

Causal Link Between Atopic Dermatitis, ADHD Remains Elusive
MDedge Psychiatry
Pharmacogenomics and Psychiatry: Time to Tailor the Treatment
MDedge Psychiatry
FDA: High-Dose Citalopram Tied to Heart Risks
MDedge Psychiatry
Facebook, Myspace Tied to Teen Substance Abuse Risk
MDedge Psychiatry
Report: CDC Surveillance of Mental Illness Scattered
MDedge Psychiatry
New DSM-5 Category May Curb Youth Bipolar Overdiagnosis
MDedge Psychiatry
Metabolic Signature Emerging in Schizophrenia
MDedge Psychiatry
Functional Training Helps Patients With Bipolar Disorder
MDedge Psychiatry
Short Course of Escitalopram Reduces Fear in Depression
MDedge Psychiatry
Neuropsychiatric Disorders Dominate Disease Burden in Europe
MDedge Psychiatry